In focus · trending topic

ovarian cancer

33 stories · following the connections

TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel

By Nasdaq OMXApr 11, 2018, 12:31 PM UTC

TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany

By Nasdaq OMXDec 15, 2017, 9:00 AM UTC

TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer

By Nasdaq OMXNov 20, 2017, 12:01 PM UTC

TESARO Expands Our Way Forward Program for the Ovarian Cancer Community and Partners With Olympic Gymnast Shannon Miller

By Nasdaq OMXSep 28, 2017, 8:30 PM UTC

ConverGene Announces Sponsored Research Agreement with MD Anderson

By Nasdaq OMXSep 18, 2017, 11:00 AM UTC

TESARO Receives Positive CHMP Opinion for ZEJULA®

By Nasdaq OMXSep 15, 2017, 11:45 AM UTC

2X Oncology Announces Validation of Drug Response Predictor (DRP) for its PARP Inhibitor 2X-121

By Nasdaq OMXAug 9, 2017, 2:30 PM UTC

Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121

By Nasdaq OMXJul 7, 2017, 12:30 PM UTC